Trial reportScientific reports2018
Bladder cancer recurrence surveillance by urine metabolomics analysis.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Discriminating high-risk cervical Human Papilloma Virus infections with urinary biomarkers via non-targeted GC-MS-based metabolomics.PloS one · 2018Trial
- Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria.Biology direct · 2026Article
- Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.Advances in urology · 2026Article
- Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.Oncology research · 2026Article
- Global research dynamics in metabolic biomarkers and cancer: a bibliometric study from 2015 to 2025.Discover oncology · 2025Review
- Association between taurine transporter SLC6A6 and breast cancer development and prognosis: a Mendelian randomization analysis.Discover oncology · 2025Article
- Targeting ketone body metabolism in mitigating gemcitabine resistance.JCI insight · 2024Article
- New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.Cancers · 2024Review
- Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer.World journal of surgical oncology · 2023Article
- Statistical methods and resources for biomarker discovery using metabolomics.BMC bioinformatics · 2023Review
- LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer.Frontiers in oncology · 2023Article
- Metabolomic and elemental profiling of blood serum in bladder cancer.Journal of pharmaceutical analysis · 2022Article
- LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.World journal of urology · 2022Review
- New bladder cancer non-invasive surveillance method based on voltammetric electronic tongue measurement of urine.iScience · 2022Article
- Efficacy of compound aluminum sulfate injection as a monotherapeutic regimen in non-muscle invasive bladder cancer patients: a retrospective single-arm cohort study.Translational andrology and urology · 2022Article
- Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.The oncologist · 2022Review
- Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.International journal of molecular sciences · 2022Review
- Article
- Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.Cancer science · 2022Article
- The effect of amino acids on the bladder cycle: a concise review.Amino acids · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non Muscle Invasive Bladder Cancer (NMIBC) is among the most frequent malignant cancers worldwide. NMIBC is treated by transurethral resection of the bladder tumor (TURBT) and intravesical therapies, and has the highest recurrence rate among solid tumors. It requires a lifelong patient monitoring based on repeated cystoscopy and urinary cytology, both having drawbacks that include lack of sensitivity and specificity, invasiveness and care costs. We conducted an investigative clinical study to examine changes in the urinary metabolome of NMBIC patients before and after TURBT, as well during the subsequent surveillance period. Adjusting by prior probability of recurrence per risk, discriminant analysis of UPLC-MS metabolic profiles, displayed negative predictive values for low, low-intermediate, high-intermediate and high risk patient groups of 96.5%, 94.0%, 92.9% and 76.1% respectively. Detailed analysis of the metabolome revealed several candidate metabolites and perturbed phenylalanine, arginine, proline and tryptophan metabolisms as putative biomarkers. A pilot retrospective analysis of longitudinal trajectories of a BC metabolic biomarkers during post TURBT surveillance was carried out and the results give strong support for the clinical use of metabolomic profiling in assessing NMIBC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.